Barclays
XENE icon

Barclays’s Xenon Pharmaceuticals XENE Stock Holding History

Barclays’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$17.6M Buy
472,443
+452,397
+2,257% +$26.9M ﹤0.01% 1330
2026
Q2 		$1.21M Sell
20,046
-218,163
-92% -$12.1M ﹤0.01% 2682
2026
Q1 		$13.9M Sell
238,209
-362,755
-60% -$16.7M ﹤0.01% 1274
2025
Q4 		$26.9M Buy
600,964
+489,664
+440% +$20.6M 0.01% 1077
2025
Q3 		$4.47M Sell
111,300
-41,470
-27% -$1.46M ﹤0.01% 2294
2025
Q2 		$4.78M Buy
152,770
+133,500
+693% +$4.35M ﹤0.01% 2174
2025
Q1 		$647K Buy
19,270
+1,143
+6% +$43.4K ﹤0.01% 3368
2024
Q4 		$711K Buy
18,127
+3,134
+21% +$130K ﹤0.01% 3605
2024
Q3 		$590K Buy
14,993
+13,903
+1,276% +$561K ﹤0.01% 3678
2024
Q2 		$42.5K Sell
1,090
-11,464
-91% -$458K ﹤0.01% 4265
2024
Q1 		$540K Sell
12,554
-99,436
-89% -$4.57M ﹤0.01% 3539
2023
Q4 		$5.16M Buy
111,990
+102,469
+1,076% +$3.62M ﹤0.01% 2063
2023
Q3 		$325K Buy
9,521
+342
+4% +$12.8K ﹤0.01% 3051
2023
Q2 		$353K Buy
9,179
+9,079
+9,079% +$361K ﹤0.01% 2955
2023
Q1 		$3.58K Buy
+100
New +$3.69K ﹤0.01% 4857
2022
Q2 		– Sell
-191
Closed -$6K – 5297
2022
Q1 		$6K Buy
+191
New +$5.72K ﹤0.01% 4687
2021
Q3 		– Sell
-40
Closed -$1K – 5053
2021
Q2 		$1K Sell
40
-142
-78% -$2.62K ﹤0.01% 4843
2021
Q1 		$3K Buy
182
+96
+112% +$1.63K ﹤0.01% 4540
2020
Q4 		$1K Buy
+86
New +$1.01K ﹤0.01% 4834
2020
Q1 		– Sell
-163
Closed -$2K – 6500
2019
Q4 		$2K Sell
163
-217
-57% -$2.28K ﹤0.01% 6254
2019
Q3 		$3K Buy
+380
New +$3.59K ﹤0.01% 6515
2019
Q2 		– Sell
-2
Closed – – 7326
2019
Q1 		$0 Sell
2
-3,725
-100% -$31.6K ﹤0.01% 7370
2018
Q4 		$24K Buy
+3,727
New +$33.1K ﹤0.01% 5821

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $102B AUM 35.16% 1-Year Est. Return

Barclays's XENE Position: Q3 2026 in Review

Barclays increased its Xenon Pharmaceuticals (XENE) stake by 2,257% in Q3 2026, buying an estimated $26.9M and bringing the position to 472,443 shares worth $17.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1330.

Barclays first reported a position in XENE in Q4 2018 and has held it in 23 quarters since. The position peaked at $26.9M in Q4 2025. 196 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • Barclays held 472,443 shares of Xenon Pharmaceuticals worth $17.6M as of Q3 2026.
  • Barclays bought 452,397 Xenon Pharmaceuticals shares in Q3 2026, an estimated $26.9M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1330 holding.
  • Barclays first reported a position in Xenon Pharmaceuticals in Q4 2018 and has held it in 23 quarters since.
  • Barclays's Xenon Pharmaceuticals position peaked at $26.9M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.